IP Library Granted Patent US 8,524,702
Granted Patent B2
US 8,524,702 · App. 12/859,182 · Granted Sep 3, 2013

Substituted benzoazepines as toll-like receptor modulators

Inventors: James Jeffry Howbert (Redmond, WA); Gregory Dietsch (Snohomish, WA); Robert Hershberg (Seattle, WA); Laurence E. Burgess (Boulder, CO); George A. Doherty (Boulder, CO); C. Todd Eary (Boulder, CO); Robert D. Groneberg (Boulder, CO); Zachary Jones (Boulder, CO)
Assignees: VentiRx Pharmaceuticals, Inc.; Array BioPharma, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,524,702
App. No.
12/859,182
Granted
Sep 3, 2013
Kind
B2
Abstract

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.

Claims (64)

1. A compound having the formula I:

or a tautomer, enantiomer or salt thereof, wherein:

Y is heteroaryl;

R 2 is selected from OR 14 and NR 6 R 7 ;

R 6 and R 7 are each independently selected from H, alkyl, cycloalkyl, heterocycle or benzyl, wherein said alkyl, cycloalkyl, or benzyl is optionally substituted with one or more groups independently selected from —F, —OR 8 , —NR 12 SO 2 R 13 , —C(═O)NR 12 R 13 or R 6 and R 7 together with the nitrogen atom to which they are attached form a heterocyclic ring, further wherein said heterocyclic ring is optionally substituted with one or more —OH;

R 8 is selected from hydrogen and alkyl, and

R 12 , R 13 and R 14 are each independently selected from H and alkyl, wherein said alkyl is optionally substituted with —OH.

2. A compound having the formula III:

or a tautomer, enantiomer or salt thereof, wherein

T is CH, CZ, or N;

U is CH, CZ, or N;

V is CH, CZ, or N;

X is CH, CZ, or N;

W is CH, CZ, or N;

R 2 is selected from OR 14 and NR 6 R 7 ;

R 6 and R 7 are each independently selected from H, alkyl, cycloalkyl, heterocycle or benzyl, wherein said alkyl, cycloalkyl, or benzyl is optionally substituted with one or more groups independently selected from —F, —OR 8 , —NR 12 SO 2 R 13 , —C(═O)NR 12 R 13 or R 6 and R 7 together with the nitrogen atom to which they are attached form a heterocyclic ring, further wherein said heterocyclic ring is optionally substituted with one or more —OH;

R 8 is selected from hydrogen and alkyl,

R 12 , R 13 and R 14 are each independently selected from H and alkyl, wherein said alkyl is optionally substituted with —OH;

Z is selected from halogen, —CN, —CONR 16 R 17 , —COOR 18 , —CH═CHCOOR 18 , and —OR 19 ; and

R 16 , R 17 , R 18 , and a R 19 are each independently selected from H, alkyl, and —CH 2 O(alkyl).

3. The compound according to claim 1 , having the formula IV:

or a tautomer, enantiomer or salt thereof.

4. A compound selected from the Group consisting of:

132

133

134

135

141

142

143

144

and tautomers, enantiomers and salts thereof.

5. The compound according to claim 1 , wherein the salt is a pharmaceutically acceptable salt.

6. A kit comprising:

a) a container comprising a pharmaceutical composition comprising a compound of claim 1 or a tautomer, enantiomer or salt thereof; and

b) optionally instructions for use.

7. A pharmaceutical composition, which comprises a compound of claim 1 or a tautomer, enantiomer or salt thereof together with a pharmaceutically acceptable diluent or carrier.

8. A method of treating cancer, comprising administering to a patient in need thereof an effective amount of a compound of claim 1 or a tautomer, enantiomer or salt thereof such that said cancer is treated, wherein said cancer is selected from biliary tract cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, intraepithelial neoplasms, leukemia, lymphoma, liver cancer, lung cancer, melanoma, neuroblastomas, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, sarcomas, skin cancer, testicular cancer, thyroid cancer, other carcinomas and sarcomas.

9. A method of treating allergy, comprising administering to a patient in need thereof an effective amount of a compound of claim 1 or a tautomer, enantiomer or salt thereof such that said allergy is treated.

10. The method of claim 9 , wherein said allergy is acquired hypersensitivity to an allergen, eczema, allergic rhinitis or coryza, hay fever, asthma, urticaria (hives), food allergies, or other atopic conditions.

11. The compound of claim 4 , selected from

141

142

143

144

133

134

135

and tautomers, enantiomers and salts thereof.

12. The compound of claim 4 , selected from

141

143

144

133

135

and tautomers, enantiomers and salts thereof.

13. A pharmaceutical composition, which comprises a compound of claim 4 or a tautomer, enantiomer or salt thereof together with a pharmaceutically acceptable diluent or carrier.

14. A method of treating cancer, comprising administering to a patient in need thereof an effective amount of a compound of claim 4 or a tautomer, enantiomer or salt thereof such that said cancer is treated, wherein said cancer is selected from biliary tract cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, intraepithelial neoplasms, leukemia, lymphoma, liver cancer, lung cancer, melanoma, neuroblastomas, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, sarcomas, skin cancer, testicular cancer, thyroid cancer, other carcinomas and sarcomas.

15. A method of treating allergy, comprising administering to a patient in need thereof an effective amount of a compound of claim 4 or a tautomer, enantiomer or salt thereof such that said allergy is treated.

16. The method of claim 15 , wherein said allergy is acquired hypersensitivity to an allergen, eczema, allergic rhinitis or coryza, hay fever, asthma, urticaria (hives), food allergies, or other atopic conditions.

17. A pharmaceutical composition, which comprises a compound of claim 3 or a tautomer, enantiomer or salt thereof together with a pharmaceutically acceptable diluent or carrier.

18. A method of treating cancer, comprising administering to a patient in need thereof an effective amount of a compound of claim 3 or a tautomer, enantiomer or salt thereof such that said cancer is treated, wherein said cancer is selected from biliary tract cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, intraepithelial neoplasms, leukemia, lymphoma, liver cancer, lung cancer, melanoma, neuroblastomas, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, sarcomas, skin cancer, testicular cancer, thyroid cancer, other carcinomas and sarcomas.

19. A method of treating allergy, comprising administering to a patient in need thereof an effective amount of a compound of claim 3 or a tautomer, enantiomer or salt thereof such that said allergy is treated.

20. The method of claim 19 , wherein said allergy is acquired hypersensitivity to an allergen, eczema, allergic rhinitis or coryza, hay fever, asthma, urticaria (hives), food allergies, or other atopic conditions.

Assignments (3)
ASSIGNEE CHANGE OF ADDRESS Recorded May 28, 2013
From: VENTIRX PHARMACEUTICALS, INC.
To: VENTIRX PHARMACEUTICALS, INC.
Reel/Frame 030498/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2011
From: HOWBERT, JAMES JEFFRY; DIETSCH, GREGORY N.; HERSHBERG, ROBERT M.
To: VENTIRX PHARMACEUTICALS, INC.
Reel/Frame 025712/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2011
From: BURGESS, LAURENCE E.; EARY, C TODD; GRONEBERG, ROBERT D.; DOHERTY, GEORGE A.; JONES, ZACHARY
To: ARRAY BIOPHARMA, INC.
Reel/Frame 025712/0864 →
Continuity (2)
Provisional Application 61234971 · Aug 18, 2009
Related Publication 20110118235A1 · May 19, 2011